|
|
||||||||
| Neurology supplements are not peer-reviewed. Information contained in Neurology supplements represent the opinions of the authors and are not endorsed by nor do they reflect the views of the American Academy of Neurology, Editor-in-Chief, or Associate Editors of Neurology. |
From the Department of Neurology, University of Wisconsin, Madison, Wisconsin.
Address correspondence and reprint requests to Dr. Raj D. Sheth, Department of Neurology, 600 Highland Ave., H6575, Madison, WI 53792; e-mail: Sheth{at}neurology.wisc.edu
Because treatment with antiepileptic drugs (AEDs) is often for years or lifelong, physicians should be aware of the metabolic changes that can be associated with AED use and the potential effects of these changes during long-term therapy. Alterations of bone metabolism leading to decreased bone mineral density, associated particularly but not exclusively with the hepatic enzyme-inducing AEDs, can worsen the risk for fractures, which is already increased in patients with epilepsy by factors such as seizure-related falls and trauma. Some AEDs are associated with weight gain, an effect that is not only distressing to many patients but may be sufficient to increase the risk for cardiovascular disease and other disorders associated with excessive body weight. The carbonic anhydrase-inhibiting properties of some AEDs can lead to metabolic acidosis. The AEDs that inhibit carbonic anhydrase are also associated with an increase in risk for renal stones, as is the ketogenic diet. Awareness of the potential metabolic disturbances associated with AED use is particularly important because many of them are subtle and may take years to become clinically apparent.
Publication of this supplement was supported by an unrestricted educational grant from GlaxoSmithKline. The sponsor has provided R.D.S. with an honorarium for his participation in this project. He has also received other honoraria from the sponsor during his career.
This article has been cited by other articles:
![]() |
A H V Schapira Present and future drug treatment for Parkinson's disease J. Neurol. Neurosurg. Psychiatry, November 1, 2005; 76(11): 1472 - 1478. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |